The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16
Introduction
Faithful cell reproduction depends on the orderly completion of S and M phase which relies on the integrity of cell cycle checkpoint controls (Hartwell and Weinert, 1989) . Defects in checkpoint controls can trigger either cell death or survival of cells carrying genetic anomalies and prone to develop genomic instability which is the hallmark of cancer cells (Hartwell, 1992) . It has been realized for some time that the p53 tumor suppressor gene is a component of DNA damage checkpoints in mammalian cells since its function is required to prevent traverse across the G1/S and G2/M boundaries in the presence of many types of genotoxic stress (O'Connor, 1997; Giaccia and Kastan, 1998) via promoting cell cycle arrest or apoptosis. It has been realized for even longer that p53 is mutated or lost in more than 50% of human cancers (Hollstein et al., 1994) which provides a hint that it would also serve in vivo to bar cell proliferation in inappropriate environmental settings, a conclusion which has been consolidated by all kinds of in vivo and in vitro investigations (Ko and Prives, 1996; Levine, 1997; Agarwal et al., 1998) . The possibility that the function of p53 in tumor suppression and in DNA damage response might represent two distinct facets of its activity has emerged recently from the discovery that oncogenic stimulation can induce its activation via a mechanism quite different from that generally used by DNA damages. Whereas the latter utilizes protein kinases to phosphorylate p53 at various sites mostly within its N-terminal transactivation domain and to disrupt its interaction with its target and negative regulator, Mdm2 (Prives, 1998) , the first relies on the expression of the Arf proteins (Quelle et al., 1995; Della Valle et al., 1997) , encoded by the late-identified Arf (alternate reading frame) transcript of the Ink4a gene (Quelle et al., 1995; Duro et al., 1995; Stone et al., 1995; Mao et al., 1995) . Human p14
Arf

, like mouse p19
Arf , stabilizes p53 owing to its capability to interact directly with Mdm2 (Pomerantz et al., 1998; Zhang et al., 1998; Kamijo et al., 1998; Stott et al., 1998) and, thereby, to inhibit the Mdm2-mediated nuclear export (Tao and Levine, 1999; Zhang and Xiong, 1999) , ubiquitination and degradation of p53 (Honda and Yasuda, 1999) . Arf upregulation in primary cells exposed to hyperproliferative signals such as myc , E1A (de Stanchina et al., 1998) , E2F1 Dimri et al., 2000) , oncogenic ras Lin and Lowe, 2001 ) and vabl (Radfar et al., 1998; Cong et al., 1999) seems to be directly involved in stabilizing p53, the physiologic outcome being cell cycle arrest or apoptosis and, possibly, after diverting the p53 pathway, cell transformation (Sherr, 1998; Sharpless and DePinho, 1999) . A rationale for these observations is provided by the fact that Arf is a direct target gene of some transcription factors of the E2F family (Degregori et al., 1997; Bates et al., 1998) whose function is required to promote S phase entry (Harbour and Dean, 2000; Nevins, 2000) . Altogether, these data have led to the concept that, via Arf, p53 would also participate in oncogene checkpoints that guard cells against hyperproliferative signals (Sherr, 1998 ).
Yet, the mechanism how Arf proteins activate p53 is still unclear because the subcellular compartment in which p53 and Mdm2 localize preferentially is the nucleoplasm and for Arf, it is the nucleolus. Based on the results of enforced co-expression experiments, one model proposes that Arf proteins function owing to their ability to sequester Mdm2 in the nucleolus and, thence, to trap Mdm2-free p53 inside the nucleus (Tao and Levine, 1999; Weber et al., 1999 Weber et al., , 2000 Sherr and Weber, 2000) or in PML-like nuclear bodies (Zhang and Xiong, 1999) . It can not be excluded however that Arf proteins could utilize other tricks to activate p53 given that the nucleolar localization of p14
Arf is not requested for its function in human cell lines (Llanos et al., 2001) and that Mdm2 does not relocalize to the nucleolus following p19
Arf -dependent, ras-induced cell cycle arrest in primary mouse keratinocytes (Lin and Lowe, 2001) . The major caveat of in vitro studies aiming at deciphering the mechanism of p53 activation by Arf proteins in physiologic situations comes from the fact that they all rely on the artifice of ectopic overexpression because Arf is undetectable in untransformed cells and its co-expression with p53 does not occur in tumor-derived ones (Pomerantz et al., 1998; Stott et al., 1998; Bates et al., 1998; Lindstro¨m et al., 2000) . That is why a more conceptual approach to the problem should also be considered. In a recent report (David-Pfeuty et al., 2001) , we have shown that a short-term treatment of human breast carcinoma MCF-7 cells and non-immortalized IMR-90 fibroblasts with the Cdk inhibitor, roscovitine (Meijer et al., 1997) , and the CKII and RNA synthesis inhibitor, DRB (Granick, 1975; Haaf and Ward, 1996) , induces a reversible activation of p53 that is coupled with a reversible nucleolar fragmentation and blockade of 45S pre-rRNA processing and a reversible brake in G1/S transit. In other words, we were able to shift human cultured cells into a reversible G0-like state through simultaneously and reversibly activating the p53 pathway and repressing nucleolar functions. In vivo however, many cells can remain quiescent for long times before they return to G1 while recovery from the roscovitine-or DRB-induced G0 state is hardly possible past 8 h of treatment in cultured MCF-7 cells. Conceivably, normal cells in vivo might be equipped with devices allowing them to reversibly activate the p53 pathway and repress nucleolar activity over greatly extended periods of time. Now, the mechanism through which Arf apparently activates p53 would clearly be suitable to stabilize in a long-term a reversible p53 response because it would permit to accumulate at the same time high levels of Mdm2 ready to eliminate p53 as soon as the triggering signal is switched off. This hypothesis that Arf might work at extending the duration of reversible p53-mediated cell cycle arrest is already consistent with the report that NARF2 cells arrested by inducible expression of p14
Arf resume normal cycling upon removal of the inducer after 2 days . Whether this hypothesis is also relevant to physiologic situations clearly deserves further investigation. The fact that the co-expression of p14
Arf and p53 does not occur in tumor cells suggests, not only, that it is incompatible with in vitro tumor cell growth, but also, that some important aspects of the in vivo Arf regulation are preserved in p53-negative tumor cell lines. Identifying parameters involved in controlling the level of expression and subnuclear targeting of endogenous p14
Arf in this type of tumor cells might therefore be a source of information not to ignore more than those issued from the experiments of ectopic overexpression.
Here we report that both the level of expression and subnuclear targeting of endogenous p14
Arf are highly variable among clonal variants of the HeLa cell line which differ in their morphological appearance. Most remarkably also, we uncovered that endogenous, but not ectopically-expressed, p14
Arf disappears in metaphase when the nucleoli disintegrate and reaccumulates in the newly-reformed nucleoli of the daughter cells at the beginning of G1. Intriguingly however, it massively and reversibly accumulates in the nucleoplasm of early G1 and S-phase cells upon shortterm treatments with roscovitine and, at a lesser extent, DRB, that disrupt nucleolar organization. The implications of these results in relation to the possible in vivo functions of the Arf proteins are discussed.
Results
Clonal variability in levels and subnuclear localization of endogenous p14
Arf
Human p14
Arf has been reported to localize predominantly to the nucleolus (Pomerantz et al., 1998; Kamijo et al., 1998; Stott et al., 1998; Zhang and Xiong, 1999) , more precisely to its granular component (Lindstro¨m et al., 2000; Karayan et al., 2001) , in a pattern very similar to that seen originally in mouse cells (Quelle et al., 1995) . Occasionally, however, p14
Arf has been found to display a speckled staining in the nucleus of HeLa cells (Della Valle et al., 1997) , or to form nuclear bodies with Mdm2 and p53 (Zhang and Xiong, 1999) . The reports that the fraction of nucleolar p14
Arfpositive cells is highly variable from one human tumor cell line to another (Lindstro¨m et al., 2000) and that the protein is undetectable in hematopoietic human cell lines that abundantly express its mRNAs (Della Valle et al., 1997) are intriguing too.
Using the 4c6/4 monoclonal anti-p14 Arf antibody (Llanos et al., 2001) , we also observed a great heterogeneity in the p14
Arf distribution in the standard Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe Hela M cell line ( Figure 1A ) whose representatives exhibit a characteristic epithelial-like phenotype and have the propensity to form bidimensional multicellular aggregates, even at low plating densities ( Figure 1B ). Whereas protein B23 concentrates at a relatively constant rate primarily in the nucleoli of all interphase Hela M cells, three main cell types can be discriminated according to their anti-p14
Arf immunolabeling ( Figure 1A ): (i) the most individualized, wellspread cells (open arrows) that emerge from the multicellular aggregates display intensely decorated nucleoli and a few bright nucleoplasmic speckles; (ii) in some isolated well-spread cells (thick arrows), however, the number of nucleoplasmic speckles gets prominent; (iii) cells embedded within the multicellular aggregates (not shown) and the less spread isolated ones (thin arrows) exhibit a variable density of nucleoplasmic speckles and a weak, if any, nucleolar labeling.
In view of these observations, we thought of examining the p14
Arf distribution in two morphologically distinct HeLa clones: HeLa G, whose representatives present a more fibroblastoid, but wellspread phenotype and remain dispersed in sparse cultures, and HeLa S3, whose representatives grow also dispersed but do not spread very well on the substratum and appear refringent under the microscope ( Figure 1B ). Remarkably, p14
Arf accumulates at an apparent level as high as that of protein B23 almost exclusively in the nucleoli of most interphase HeLa G cells while it is essentially found in nucleoplasmic speckles in HeLa S3 cells ( Figure 1A ). Notably also and in striking contrast to protein B23, p14
Arf is not detectable above background level in most metaphase cells in anyone of the present HeLa cell lines ( Figure  1A , arrowheads), no more than in two other p537/ Arf+ tumor-derived cell lines, Saos-2 and H1299. A staining pattern quite similar to that seen in the HeLa G clone has been detected in the HeLa Tet-on cell line commercialized by Clontech which, too, displays a fibroblastoı¨d phenotype and in interphase NARF2 and NARF2/E6 cells in which p14
Arf expression is strictly dependent upon the presence of IPTG . In the two latter cell lines, however, its distribution closely resembles that of protein B23 even in mitotic and early G1 cells ( Figure 1A , lower panel, arrowheads) which demonstrates, first, that the 4c6/4 anti-p14
Arf antibodies do interact with p14 Arf when it is present in metaphase and, most importantly, that the mitosis-specific regulation of endogenous p14
Arf is lost by the ectopically-expressed one. Neither the anti-B23 labeling ( Figure 1A ) nor the nucleoli (according to phase contrast microscopic observations; not shown) of the HeLa S3 cells differ grossly from those of the HeLa G and of the HeLa M cells and the anti-p14
Arfdecorated nuclear speckles do not coı¨ncide with any visible phase contrast (not shown) nor anti-B23-decorated ( Figure 1A ) structures.
The JR14 rabbit polyclonal anti-p14 Arf antiserum (or the 4c6/4 mouse monoclonal antibody) readily detected a 14 kDa band on immunoblots of lysates from asynchronous Hela G cells whose intensity is 4 -6 times higher than that from lysates of asynchronous Hela M and HeLa S3 cells and from nocodazolearrested mitotic Hela G cells, but, roughly 1/3 of that from lysates of NARF2/E6 cells treated for 24 h with 1 mM IPTG (Figure 2) . Contrastingly, the 38 kDa band corresponding to protein B23 is about of the same strength in all lanes (Figure 2) .
Differential distribution of nucleolar proteins B23, p14
Arf and Ki-67 throughout mitosis in HeLa G cells Mammalian cell nucleoli disaggregate at the onset of M-phase into distinctive subcomponents that redistribute to different cellular structures and in which are selectively stored the dislocated parts of the ribosome factory during the course of mitosis (Dundr et al., 2000; Savino et al., 2001) . There is good evidence also that nucleoli reconstruct in postmitotic cells owing in part to conveyance of material from the mother cell. This is true in particular for nucleolar proteins involved in pre-rRNA processing (like protein B23) which reenter the nucleolus via the PNB pathway approximately at a stage where their function is requested (Savino et al., 1999) . As it is clearly depicted in Figure 3A , the dynamics of p14
Arf during the cell cycle does not at all follow these rules, even in HeLa G cells in which, yet, p14
Arf distributes almost identically to protein B23 throughout the greatest part of interphase. During late G2 phase (a) and prophase, p14
Arf , similarly to protein B23, accumulates massively inside large aggregates that encompass the stillcompacted nucleoli and from which chromosomes are excluded (long arrows); at metaphase, however, the p14
Arf and B23 patterns obviously start diverging: Figure 2 Western blot analysis of the expression of protein B23 and p14
Arf performed on equal amounts of whole-cell lysates from: NARF2/E6 (24 h IPTG, 1 mM); HeLa M; HeLa S3; HeLa Tet-On; HeLa G; HeLa G (8 h Roscovitine (Ro), 40 mM); HeLa G (8 h DRB, 60 mM); HeLa G, mitotic Arf is barely detectable in most cells in which protein B23 highly concentrates in perichromosomal areas and in the entire cell interior; in early telophase (d), many Arf-/B23+NDFs (thin arrows) and PNBs (arrowheads) can be detected; in late telophase (e), p14
Arf weakly concentrates at sites where protein B23 already accumulates significantly; at last, p14
Arf rapidly collects in early G1 phase (f) up to reaching that of protein B23 in the newly reformed nucleoli. (B) Double immunolabeling of HeLa G cells with mAb 4c6/4 anti-p14
Arf and goat anti-Ki-67 antibodies, overlay image and Dapi coloration. In prophase (a), Ki-67 deserts the nucleolar aggregates to which p14
Arf remains associated (long arrows) and selectively decorates the condensing chromosomes, a location which it keeps in metaphase, anaphase and early telophase (b, c and d, respectively) 
. (C) Double immunolabeling of HeLa G cells with mAb 4c6/4 anti-p14
Arf and rabbit anti-H1Pi antibodies, overlay image and Dapi coloration. The anti-H1Pi antibodies always decorate intensely the p14 Arf -negative metaphase (b) cells. They also concentrate, although at a much lesser extent, in the p14
Arf -positive nuclear aggregates observed in late G2 and prophase (long arrows; a) and around the highly condensed chromosomes of early telophase cells (thin arrows, d) Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe p14
Arf becomes barely detectable in many metaphase cells (75 -80%; b cells) and in anaphase (c cell), at times when protein B23 highly concentrates in perichromosomal areas and in the entire cell interior; in early telophase (d cells), numerous cytoplasmic NDFs (thin arrows) and nuclear PNBs (arrowheads) which brightly stain for protein B23 but faintly for p14
Arf , re-emerge; in late telophase, a low level of p14
Arf is sometimes seen at sites where protein B23 already accumulates significantly (e cells); finally, as the chromosomes keep decondensing in early G1 phase (f cells), the p14
Arf level rapidly rises up to reaching that of protein B23 in the newly reformed nucleoli.
Therefore, endogenous p14 Arf apparently integrates postmitotic nucleoli later than protein B23 in HeLa G cells. Our observations also suggested that the slow kinetics of nucleolar reappearance of p14
Arf was probably consequent upon the fact that its stock is dramatically depleted at metaphase and has therefore to replenish in post-mitotic cells. We then questioned whether the nucleolar Ki-67 protein which, too, enters the nucleolus later than protein B23 (Savino et al., 1999) , behaved like p14
Arf during mitosis. As a matter of fact, the pattern of expression of Ki-67 throughout mitosis resembles neither that of p14
Arf nor that of protein B23, as shown in Figure 3B : in prophase (a cell), Ki-67 deserts the still-aggregated nucleolar structures to which both protein B23 and p14
Arf are intimately connected (long arrows); instead, it associates selectively with the condensing chromosomes, a location which it keeps in metaphase, anaphase and early telophase (b, c and d cells); in late telophase and early G1 phase, its amount inside PNBs and newly forming nucleoli rises more slowly than that of protein B23 (Savino et al., 1999) but faster than that of p14
Arf (not shown).
Double immunolabeling experiments with anti-p14
Arf and anti-phospho-Histone H1 (H1Pi) antibodies were performed to determine if there was a possible correlation between the timing of disappearance of p14
Arf and that of the cyclin B1/Cdk1 kinase activity at metaphase. As illustrated in Figure 3C , the level of H1Pi is always high in the p14
Arf -negative metaphase cells present in unsynchronized populations (b cell) as well as in nocodazole-arrested mitotic cells, many of which lose p14
Arf during the block (not shown). Interestingly, concentrations of anti-H1Pi antibodies higher than in the rest of the cell are often found in the p14
Arf -and B23-positive aggregates present in late G2 and prophase (long arrows, a cell) and in association with the highly condensed chromosomes of early telophase cells (thin arrows, d cells).
A short-term treatment of HeLa G cells with roscovitine or DRB induces reversible nucleolar fragmentation and nucleoplasmic accumulation of p14 Arf Thus, although endogenous p14
Arf localizes predominantly to the nucleolus of interphase HeLa G cells very similarly to protein B23, it generally disappears at metaphase when the nucleoli disassemble and protein B23 redistributes in perichromosomal areas and diffusely throughout the whole cell volume. This strongly suggested that p14
Arf might be unstable in these cells when unbound to appropriate nucleolar structures and enforced to relocalize to the nucleoplasm. We wondered then whether its nucleoplasmic accumulation would not be prohibited also under conditions outside mitosis in which the nucleoli disintegrate as occurs following treatment with roscovitine (David-Pfeuty, 1999 ) and DRB in a number of untransformed and tumor-derived cell lines (Granick, 1975; Haaf and Ward, 1996; David-Pfeuty et al., 2001) . A time of exposure of the cells to either 40 mM roscovitine or 60 mM DRB as short as 1 h is sufficient to induce a full disintegration of the nucleolar architecture into components which scatter through the nucleus, as evidenced by phase contrast microscopy ( Figure 4A, C) . Immunofluorescence observations, on the other hand, allowed to distinguish three main cell types on the basis of their anti-p14
Arf immunolabeling in roscovitine-treated cell populations ( Figure 4A ): (i) cells (marked with asterisks) in which both the antip14
Arf and anti-B23 antibodies decorate mainly dark nucleolar bodies (thin arrows) and, at a much lesser extent, the nucleoplasm; (ii) others (large and short arrows) in which the nucleoplasmic concentration of p14
Arf is prominent and exceeds largely that of protein B23 which remains associated first with nucleolar bodies (thin arrows); (iii) cells, identifiable as postmitotic, early G1 cells by phase contrast microscopy which revealed the presence of a midbody and of numerous PNBs (open arrows and c region), in which both the anti-p14
Arf and anti-B23 antibodies strongly accumulate in a diffuse pattern throughout the whole nuclear space in varying ratios from one cell-pair to another. Double immunolabeling experiments with anti-p14
Arf and anti-cyclin A antibodies permitted in addition to show that the nucleoplasmic concentration of p14
Arf in roscovitine-treated cells varies in proportion to that of cyclin A ( Figure 4B ), except in postmitotic cells. It is noteworthy that 40 mM roscovitine is insufficient to visibly deplete the level of phospho-Histone H1 in mitotic cells, although it visibly but not totally reduces that in interphase cells, as indicated by double immunofluorescence observations with anti-p14
Arf and anti-H1Pi antibodies (not shown). On the other side, 60 mM DRB generates effects somewhat similar to those of 40 mM roscovitine, apart from the fact that p14
Arf accumulation in postmitotic cells occurs in both the nucleus and the cytoplasm after DRB treatment ( Figure 4C) . Finally, the effects of both roscovitine and DRB on p14
Arf distribution were fully reversible initially, as they are on nucleolar organization (David-Pfeuty et al., 2001), and p14
Arf relocated quasi-totally to the nucleoli as soon as these were fully reconstructed, that is, within 1 -2 h after drug release (not shown).
Longer exposure (8 h) to either roscovitine or DRB resulted in an accumulation of cells in G1 and G2/M phase (5G1/S/G2-M4=54/33/13 and 58/30/12, respectively, versus 48/44/8 in controls) and beginning of appearance of chromatin figures of apoptosis, Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe
Figure 4 (A) Double immunolabeling with mAb 4c6/4 anti-p14
Arf and goat anti-B23 antibodies of HeLa G cells treated with 40 mM roscovitine for 1 h, overlay and magnified phase contrast image of regions delineated on the overlays: (1) the asterisks designate cells which express low levels of both p14
Arf and protein B23 mostly concentrated in dark nucleolar bodies (thin arrows); (ii) the large, short arrows point to a cell which displays a prominent nuclear anti-p14
Arf immunostaining, largely exceeding that of protein B23 which is still associated primarily with nucleolar bodies (thin arrows); (iii) both p14
Arf and protein B23 strongly accumulate in a diffuse pattern throughout the whole nuclear space in postmitotic cells identifiable
by their midbody (open arrows and c region). (B) Double immunolabeling of HeLa G cells treated with 40 mM roscovitine for 1 h with mAb 4c6/4 anti-p14
Arf and rabbit anticyclin A antibodies, and Dapi coloration showing that the nucleoplasmic concentration of p14
Arf in roscovitine-treated cells varies in proportion to that of cyclin A. (C) Double immunolabeling of HeLa G cells treated for 1 h with 40 mM roscovitine or 60 mM DRB, or untreated (Control), with mAb 4c6/4 anti-p14
Arf and goat anti-B23 antibodies, overlay and phase contrast image (C Ph). Emphasis is laid here on postmitotic cells (whose midbody is marked out by an open arrow). In control cells, p14
Arf barely accumulates in NDFs, PNBs (thin arrows) and small-sized nucleoli (open arrowheads). 1 h-treatment with either roscovitine or DRB prevents normal nucleolar reassembly in postmitotic HeLa G cells; however, it does not prevent accumulation of p14
Arf inside the nucleoplasm in the presence of roscovitine and inside both the nucleus and the cytoplasm, in the presence of DRB Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe according to the Dapi coloration (not shown). Yet, survivor cells recovered, upon removal of the drugs, as fast as after 1 h-treatment. The level of expression of both p14
Arf and protein B23 did not decline much by 8 h-treatment (Figure 2 ) and their subcellular distribution did not differ greatly from that seen after 1 htreatment, except that postmitotic cells invaded with a high diffuse immunolabeling for both p14
Arf and protein B23 (such as those pointed by open arrows in Figure 4) were not any longer visible. The whole cell populations eventually died upon continued exposure to roscovitine, somewhat faster for HeLa G than for HeLa S3 and HeLa M cells -DRB is metabolized very fast in HeLa cells as observed earlier in MCF-7 cells (David-Pfeuty et al., 2001) so that its action can not be followed beyond 8 h.
Discussion
The main debate as to how nucleolar Arf proteins stabilize nucleoplasmic p53 and Mdm2 has focused up to now on guessing in which subcellular compartment they actually manage to activate the p53 function. But, the issue when and in what particular context has somewhat been neglected. Two recent reports have challenged the earlier view that they would function by sequestering Mdm2 in the nucleolus or in nuclear bodies : one, by showing that Mdm2 does not relocalize to the nucleolus following p19
Arfdependent, ras-induced cell cycle arrest in primary mouse keratinocytes (Lin and Lowe, 2001) ; the other, by demonstrating that nucleoplasmic forms of Arf retain the capacity to stabilize Mdm2 and p53 in human cells (Llanos et al., 2001) . As emphasized by the latter authors, when Arf is expressed at supraphysiological levels, it is always possible that the massive nucleolar accumulation induced would mask the presence of a minor nucleoplasmic pool capable alone to execute the physiologic response. Given the further observation that Arf expression in naturally-occurring systems appears to be regulated at the level of translation and/or protein stability and to be highly sensitive to environmental parameters (Lindstro¨m et al., 2000; Della Valle et al., 1997) , it is a matter of paramount importance to identify the parameters which, spatially and temporally, control the level of expression and subnuclear targeting of the endogenous protein.
Here we show that both the level of expression and subnuclear targeting of p14
Arf are highly variable among clonal variants of the HeLa cell line which differ in their morphological appearance. In the original epithelial-like HeLa cells, there is a low level of p14
Arf which partitions among the nucleolus and the nucleoplasm in varying ratios from one cell to another in subconfluent cultures, but, which is exclusively nucleoplasmic in confluent ones. Strikingly, two different fibroblastoı¨d-like HeLa clones express much higher levels of p14
Arf which segregates almost exclusively in the nucleolus during interphase. Yet, HeLa S3 derivatives which also have lost epithelial-like features but exhibit a lower spreading capacity than the fibroblastoid derivatives, express a low level of p14
Arf which resides mostly in the nucleoplasm. Interestingly, clonal variants which we obtained from the Saos-2 (p53-/Rb-/Arf+) cell line do not exhibit such a variability in morphology and in p14
Arf distribution and level of expression. Like most cervical carcinoma cells, HeLa cells harbor intact p53 and Rb genes whose growth suppressor function is kept dormant by the HPV E6 and E7 oncoproteins, respectively, but can be reactivated through repression of E6/E7 transcription by HPV E2 proteins (Goodwin and Dimaio, 2000) . Perhaps, variation in the residual level of activity of the p53 and Rb pathways might be responsible for the occurrence of this perplexing phenomenon in HeLa cells.
Another major finding of this work is that, although p14
Arf and protein B23 distribute similarly through the nucleolus of interphase HeLa G cells, p14
Arf , but not protein B23, suddenly disappears in metaphase, reminding of the behaviour of mitotic cyclins. Consistently, its level is still low in the B23-decorated NDFs and PNBs which re-emerge in late telophase. Afterwards, it rapidly collects in the newly reformed nucleoli of early G1 cells, presumably when efficient translational activity is restored. Importantly, this regulation of endogenous p14
Arf is lost by ectopically-induced p14 Arf . The behaviour of endogenous p14
Arf during mitosis contrasts also with that of many other hosts of the granular and dense fibrillar compartments of the nucleolus (including Ki-67 which enters nucleoli at the latest stage of nucleologenesis) which all remain present and redistribute to some subcellular structures during mitosis (Gautier et al., 1992; Dundr and Olson, 1998; this work) . A possible explanation was that p14
Arf is unstable when unbound to fully assembled nucleoli. This yet would not be a general feature because its nucleoplasmic level dramatically rises in early G1 cells upon 1 h-exposure to 40 mM roscovitine that is sufficient to induce a full nucleolar disintegration. Since roscovitine provokes a premature exit from mitosis in HeLa cells (Sirri et al., 2000 ; not shown), it is conceivable that this could permit the birth of daughter cells that would have inherited a maternal pool of p14
Arf . This effect is specific for roscovitine because 1 h-DRB (60 mM) treatment (which also totally unravels the nucleoli) redistributes p14
Arf in both the nucleoplasm and the cytoplasm of early G1 cells. DRB, however, contrary to roscovitine, does not provoke a premature exit from mitosis and also potently inhibits RNA polymerase II (Haaf and Ward, 1996) , so that its effects should be more complex. These striking observations provide a hint that Arf might be an essential component of the mitotic exit checkpoint and could account also for the reported implication of Arf proteins in the process of replicative senescence (Lundberg et al., 2000) . It can be anticipated indeed that untimely exit of mitosis and, more generally, exit of mitosis before total elimination of the maternal pool of Arf, could induce in p53+/ Arf+ cells a premature activation of the p53 pathway and, depending on concurrent signals, reversible or irreversible cell cycle arrest or apoptosis. Interestingly, Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe reversible p53-dependent G1 arrest induced by microtubule disruption (Khan and Wahl, 1998 ) depends on p19 Arf in MEFs (Khan et al., 2000) . The timing of inactivation of the cyclin B/Cdk1 kinase and that of p14
Arf disappearance in metaphase HeLa G cells differ and should probably then be mediated by distinct mechanisms. The first is known to rely on the anaphasepromoting complex (Morgan, 1999) . As to p14
Arf , we failed to stabilize it in metaphase upon 7 h incubation in the presence of 10 mM MG-132 proteasome inhibitor (not shown). What regulates Arf unstability in mitosis is presently under investigation.
A stable nucleoplasmic relocalization of p14 Arf also occurs beyond early G1 phase upon roscovitine-and DRB-treatment, yet its apparent rate rises as cells progress in the cell cycle, which is somewhat expected since Arf is a direct target gene of E2F. The effects of roscovitine and DRB on both nucleolar organization and p14
Arf distribution are fully reversible initially but eventually become irreversible with time, the cells starting visibly to die past 8 h-treatment. This toxicity is likely to be due to the fact that the nucleolar unravelling induced by the two compounds is associated with an arrest of pre-rRNA processing in a variety of cells (David-Pfeuty et al., 2001; Sirri et al., 2002) , an effect that ultimately should end up in depleting the ribosome supply below a threshold required for survival.
Together, our data show that short-lived perturbations in cell cycle progression and in nucleolar organization can trigger a swift, totally reversible and apparently harmless nucleoplasmic accumulation of endogenous Arf that is more extensive at the very beginning of G1 phase and after G1/S transit in HeLa cells in which both the p53 and Rb pathways are dormant. Remembering that the p53 nuclear level peaks between mid-G1 and the G1/S border in p53-expressor cells in which Arf is either undetectable or not expressed (Takahashi and Suzuki, 1994; David-Pfeuty et al., 1996; David-Pfeuty, 1999) , the presence of Arf in p53+/Arf+ cells could in principle work at broadening the cell cycle window during which the p53 pathway can be reversibly activated, and, thereby, contribute to extend the sphere of activity of p53. For instance, it stands to reason that both speeding and amplifying the p53 response in early G1 might help trigger a durable and reversible cell cycle arrest before the mitogenstimulated pathways would have generated irreversible effects. Remind that inducible overexpression of p14
Arf in NARF2 cells triggers a cell cycle arrest which can still be released after 2 days . Expectedly also, an increased nuclear level of Arf at, and beyond G1/S transit should sensitize cells to p53 in the presence of stress signals inefficient per se at stabilizing p53 in the nucleus then. The physiologic outcome should be a reinforcement of G1/S arrest if p21 induction is still permitted, but, cell death if it is not and if S phase entry occurs. Interestingly, altered kinetics of p53 and p21 induction have been held responsible for the lack of long-lasting G1 arrest in DNA-damaged p19
Arf -null MEFs (Khan et al., 2000) .
Our previous work (David-Pfeuty et al., 2001 ) enabled us to propose that the capacity of the cyclin E/Cdk2 complex activity to function as master regulator of restriction (R)-point transit (Pardee, 1974; Vidal and Koff, 2000) takes root in the ability of the complex to serve as a common upstream regulator of three distinct pathways involved in inducing cell cycle arrest, S-phase entry and cell growth, whose major effectors are p53, E2F1 and nucleolar activities, respectively. The complex should therefore be able to perform a variety of tasks within the three pathways which all should be readily reversible before R-point transit. This could be achieved owing to devices which operate before the R-point to minimize imbalance and/or interferences between the various cyclin E/Cdk2-activated pathways that would compromise their capacity of reversing, if necessary. Now, the Arf proteins can possibly interfere with each of these pathways. They could regulate some nucleolar activities since they carry nucleolar localization signals Lohrum et al., 2000) and can accumulate in the nucleolus. (Our preliminary observation that long-term (48 h) overexpression of p14
Arf in NARF2 cells induces a full nucleolar disintegration in 530% of the cells supports indeed this hypothesis; T David-Pfeuty, unpublished data.) They can also block reversibly entry in S phase by activating a reversible p53 pathway . Finally, human Arf has been shown to interact physically with E2F1 and inhibit its transcriptional activity (Eymin et al., 2001) . It is conceivable then that the Arf proteins could participate in vivo in devices that are in charge to allow the various cyclin E/Cdk2-dependent pathways to evolve on an autonomous and well-balanced mode for a certain period of time after exit from G0. This in turn would permit G1 phase events to occur reversibly until a critical no return point, namely, the R-point.
Materials and methods
Cell lines: growth conditions, synchronization and chemicals
The parental ATCC CCL-2 epithelial-like HeLa cell line, called afterwards HeLa M, and the Saos-2 osteosarcoma cell line were a gift from Evelyne May (CEA, Fontenay-auxRoses, France). The H1299 lung adenocarcinoma cell line and the HeLa S3 and HeLa G (Bosselut et al., 1990) clonal variants were provided by Thierry Soussi (Curie Institute, Paris, France), Tony Hunter (The Salk Institute, La Jolla, CA, USA) and Jacques Ghysdael (Curie Institute, Orsay, France), respectively. The HeLa Tet-On cell line was from Clontech (Palo Alto, CA, USA). All cells were grown in DMEM supplemented with antibiotics and 10% fetal calf serum, at 378C, in a 5% CO 2 humidified atmosphere. The NARF2/E6 cell line was provided by Gordon Peters (ICRFL, London, UK). It has been obtained by transfection of pBabepuro-E6 in NARF cells (derived from U2OS human osteosarcoma cells expressing inducibly p14
Arf upon addition of IPTG ). The NARF2/E6 cells are grown in DMEM+10% FCS containing 150 mg/ml hygromycin, 300 mg/ml geneticin and 1.25 mg/ml puromycin. Arf subnuclear localization and function T David-Pfeuty and Y Nouvian-Dooghe Mitotic cells accumulating during a 8 h-exposure to 100 nM nocodazole (Sigma, l'Isle d'Abeau Chesnes, France) were detached by flushing and collected by centrifugation.
The chemical inhibitors of Cdk, roscovitine, was purchased from France Biochem (Meudon, France) and the CKII and RNA synthesis inhibitor, DRB, from Sigma.
Immunochemical, staining reagents and immunofluorescence procedure
The 4c6/4 mouse monoclonal (Llanos et al., 2001 ) and JR14 rabbit polyclonal anti-p14
Arf antibodies were kindly provided by Gordon Peters and the rabbit polyclonal anti-cyclin A antiserum, by Tony Hunter. The goat polyclonal anti-B23 (C-19, sc-6013) and anti-Ki-67 (C20, sc-7844) IgGs were purchased from Tebu (Le Perray-en-Yvelines, France) and the rabbit polyclonal anti-phospho-Histone H1 (H1Pi) antibodies (UBI), from Euromedex (Souffelweyersheim, France). Counterstaining of DNA was achieved using Dapi (1 mg/ml; Sigma). Pulse labeling of cells with BrdUrd (Sigma) was performed to identify cells undergoing DNA replication by flow cytometry. The rat monoclonal anti-BrdUrd antibody (MAS 250b) was provided as a supernatant fluid from a hybridoma cell line (Interchim, Montluc¸on, France). Secondary antibodies (Interchim, Montluc¸on, France) were Fab fragments from goat or donkey IgGs conjugated either with FITC or TRITC.
Double-or triple-fluorescence cell labeling is currently performed after fixation with 3% paraformaldehyde and subsequent permeabilization by treatment with 0.1% Triton X-100 at room temperature. Immunolabeling with anti-cyclin A provides a reliable tool to determine cell cycle position during interphase as cyclin A first appears in the nucleus shortly prior to the onset of S phase and then steadily accumulates during progression through the S and G2 phases, reaching a maximal level in early prophase (Girard et al., 1991) . Alternatively, immunolabeling with anti-phosphoHistone H1 (H1Pi) antibodies can be used for a similar purpose since histone H1 is a very good in vivo and in vitro substrate for cyclin/Cdk complexes. The Dapi coloration is particularly useful to identify a specific mitotic stage starting from early prophase in which early chromosome condensation is reflected by the appearance of a characteristic punctate pattern as well as to detect apoptotic cells which display different types of aberrant chromatin structures (Wyllie et al., 1980) . Phase contrast microscopy is used to recognize postmitotic cells which typically exhibit a low degree of spreading and remain connected through a visible midbody. This technique permits also to visualize nucleolar structures with some details. Fluorescence microscopy was performed as described previously (Savino et al., 2001 ) with a Leica DM RXA microscope equipped with a krypton/argon ion laser and a UV filter (which allowed the detection of Dapi, fluorescein and rhodamine at respectively 350, 492 and 550 nm) using 406 and 1006 PlanApo objectives. Images were acquired using a MHz Micromax 1300Y interline CCD camera (Roper instruments) with the use of Metamorph Image Software (Universal Imaging Corp, West Chester, PA, USA).
Immunoblotting experiments
Cellular extracts for immunoblotting are prepared in lysis buffer containing 10 mM Tris-HCl (pH 7.2), 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 5 mM EDTA, 5 mM dithiothreitol, a mixture of chymostatin, leupeptin, antipapaı¨n and pepstatin (2 mg/ml each) and 100 kallikrein inactivator units of aprotinin. Protein separation is carried out by electrophoresis on SDS/polyacrylamide gels (16% acrylamide/0.33% bisacrylamide) after boiling the samples for 3 min in 26SDS sample buffer. The fractionated proteins are transferred to nitrocellulose at 600 mA for 3 h in cold room and, after blocking, the transfer membranes are incubated in the presence of the appropriate antibody solution overnight at 48C. After several washes, they are exposed to horseradish peroxidase-conjugated antibody and detection of the immune complex is performed using the Pierce ECL Western blotting SuperSignal system (Interchim).
Flow cytometry and Trypan blue assays
Prior to detection of BrdUrd-labeled cells as described (Wilson et al., 1985) , the cells are pulse-labeled with 30 mM BrdUrd for 15 min, washed in PBS, trypsinized and collected by centrifugation. After fixation with 75% ethanol at 7208C for 10 min, the nuclei are isolated following treatment with 0.5% pepsin in 0.1 N HCl for 20 min and cellular DNA is partially denatured with 2 N HCl for 20 min at 378C. After several washes, they are incubated at RT successively with rat anti-BrdUrd antibodies (1 h) and with FITC-conjugated goat anti-rat IgG secondary antibody (1/2 h). They are then washed twice in PBS and stained with 25 mg/ml propidium iodide for 30 min at RT. Data are collected using a FACScan flow cytometer (Becton Dickinson & Co., San Jose, CA, USA). The green fluorescence associated to BrdUrd-labeled cells is measured at 520 nm and the red one of PI at 4620 nm. The G1/S/G2-M ratio is determined from the bivariate BrdUrd vs DNA content plots by counting the number of dots in the appropriate area defined after performing control experiments in which the incubation with BrdUrd has been omitted. Counting is made on 10 000 cells.
The rate of cell death as a function of the time of exposure to the different compounds is estimated by the Trypan blue exclusion assay. At the desired time, the medium containing floating cells is recolted and the adhering cells are detached by trypsinization and collected with the floating ones. Cell viability is determined after adding an equivalent volume of a 0.125% Trypan blue solution to an aliquot of the whole suspended cells and counting under the microscope the proportion of unstained versus total cells deposited in a hemacytometer. For each time point, an average value of cell viability is obtained from at least five counts over different fields of 100 cells.
Abbreviations
Cdk, cyclin-dependent kinase; CKII, casein kinase II; DRB, 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole; BrdUrd, 5-bromodeoxyuridine; Dapi, 4',6-diamidino-2-phenylindole; MEFs, mouse embryo fibroblasts; NDFs, nucleolus-derived foci; PNBs, prenucleolar bodies; DMEM, Dulbecco's modified Eagle's medium; IPTG, isopropyl b-Dthiogalactopyranoside; FITC, fluorescein isothiocyanate; TRITC, tetramethyl rhodamine isothiocyanate.
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